Navigating Bleeding, Thrombosis, and Antithrombotic Management in Transcatheter Aortic Valve Replacement

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Medicine

Background:

• Transcatheter aortic valve replacement (TAVR) is a less invasive treatment for aortic stenosis.
• Post-TAVR management presents challenges, especially regarding antithrombotic strategies due to competing bleeding and thrombosis risks.

Purpose of the Study:

• To review current antithrombotic strategies for TAVR patients.
• To examine guidelines, clinical data, and the role of direct oral anticoagulants.
• To discuss management of comorbidities like atrial fibrillation and coronary artery disease in TAVR patients.

Main Methods:

• Literature review of American and European guidelines.
• Analysis of clinical trial data on anticoagulation and antiplatelet therapy.
• Exploration of direct oral anticoagulants' role in TAVR.

Main Results:

• Current guidelines offer varying recommendations for antithrombotic therapy post-TAVR.
• Personalized approaches are crucial, considering patient-specific risks and comorbidities.
• Direct oral anticoagulants show promise but require further investigation in TAVR populations.

Conclusions:

• Optimizing antithrombotic therapy post-TAVR requires balancing bleeding and thrombotic risks.
• Further research is needed to refine recommendations and improve patient outcomes.
• Personalized management strategies are key to mitigating complications like stroke and bleeding.